about
White matter damage and systemic inflammation in Parkinson's disease.Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson's Disease (PD).Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues.Induced Pluripotent Stem Cell Neuronal Models for the Study of Autophagy Pathways in Human Neurodegenerative Disease.The use of nonhuman primate models to understand processes in Parkinson's disease.Animal models of α-synucleinopathy for Parkinson disease drug development.Progress toward an integrated understanding of Parkinson's disease.Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies.Proteomic mapping of differentially vulnerable pre-synaptic populations identifies regulators of neuronal stability in vivoThe End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging.E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation.Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease.Parkinson's Disease Is Not Simply a Prion Disorder.Ifngr1 and Stat1 mediated canonical Ifn-γ signaling drives nigrostriatal degeneration.Network connectivity determines cortical thinning in early Parkinson's disease progression.Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain.Altered neurofilament protein expression in the lateral vestibular nucleus in Parkinson's disease.Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.Parkinson's Disease, the Dopaminergic Neuron and Gammahydroxybutyrate.Prying into the Prion Hypothesis for Parkinson's Disease.DARS2 protects against neuroinflammation and apoptotic neuronal loss, but is dispensable for myelin producing cells.Pla2g6 Deficiency in Zebrafish Leads to Dopaminergic Cell Death, Axonal Degeneration, Increased β-Synuclein Expression, and Defects in Brain Functions and Pathways.Cell-Specific RNA Quantification in Human SN DA Neurons from Heterogeneous Post-mortem Midbrain Samples by UV-Laser Microdissection and RT-qPCR.A Clinical and Molecular Genetic Study of 50 Families with Autosomal Recessive Parkinsonism Revealed Known and Novel Gene Mutations.Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.Regional levels of physiological α-synuclein are directly associated with Lewy body pathology.LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.Metabolism of Dopamine in Nucleus Accumbens Astrocytes Is Preserved in Aged Mice Exposed to MPTP.Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons.Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation.Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity.α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration.Astrocyte-specific DJ-1 overexpression protects against rotenone-induced neurotoxicity in a rat model of Parkinson's disease.Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?Taurine protects dopaminergic neurons in a mouse Parkinson's disease model through inhibition of microglial M1 polarization.
P2860
Q33781574-29748C40-CDA4-4A4F-84AA-81FE10380FA9Q33831798-9A3CF0DC-3104-401E-A0AE-74401AE84FA3Q38598375-1BC15800-5EBC-44D0-AD0F-E8695301C3E3Q38603276-393AA168-0FB8-48DA-90C5-A686FBE3ACA2Q38695115-67CCB336-4468-4C67-8736-2019EA9AD0E3Q39208290-523C0194-F963-4E52-B0B5-D2B41AFBF415Q40106906-126C360E-41B9-4C82-81DF-E353A9428DD6Q41012014-B693DD64-9E59-4489-9B29-BAA6C0913AD4Q41589030-5F79701D-0D49-4BD9-87D4-3CC6DDEFE748Q42069362-6A5116EB-FE42-419A-8BA3-BFBA942ECCDEQ42700405-47349BB8-A308-4FA3-B6F7-88F2F5A5C51CQ46308077-0332F847-B611-4955-AE11-6BEB7BB9E043Q46310564-B487E3F6-BDD3-48E7-8061-5727BDBDCF8FQ46354756-9A44FDDF-DB44-4A0F-9B14-E1E9FF63A636Q46391552-5EBF5E23-FCE6-4509-92C8-F4BD86068424Q47217972-0C691D35-ED0D-4A94-9F2A-69A1DE317BB2Q47314960-4A2A68B7-FB20-4DD4-B997-1DC79709C2AFQ47382007-6D8CDE9B-5155-47E8-A5F9-415417F5CCE3Q47566459-6BD583CD-8B69-4032-8140-0398027DDDBCQ47614352-B2AA11DB-6AFA-4636-A17F-53A24A94A349Q47618091-E6177F84-AC8B-4B5E-BF6D-2D5FA53A0601Q47619917-DA03945D-B15A-4793-975E-8D1769A3071BQ47640970-9CCF8779-A843-4AF4-A7E1-64B838F66AD9Q47665674-803E7EF0-4F25-4563-860B-EAF40D692606Q47687020-F472E0A7-3629-4155-9A4D-CC10CBA6FA2AQ47854549-98017A5C-70E7-4B8D-BB35-DC3B378B63AAQ47854637-0D6FF357-58CF-4701-99A6-816C21A08784Q47871666-94E396FF-96D1-475A-A852-FB58EE12AC62Q48165108-2993E38A-FD19-4876-8139-B9963FB379C6Q48310927-8A249954-F118-4359-8009-2D53A6D38B2DQ48560989-83E162C5-A8D9-45E7-98D0-4D2384946AD9Q49499665-8C2C03DD-81B5-4A86-9F08-626672AB40D5Q50031789-CF590A38-02AB-4E31-B2ED-3E11CC6A1402Q50109111-E39ECC2A-B73D-4CB3-8252-2D1D08C7C686Q51732455-20C0B525-BA31-4974-89B3-E4011494C87AQ51744776-FE1C02C1-4F0C-40B5-80B4-78EFE5D42EAEQ52092700-DAA91DCD-8E5F-4DEF-B847-18BAE91D0850Q52591608-E2054334-D5D7-4B01-ACE9-EE090C7D0CF2Q52624714-7FB3B42C-D68A-4511-A61C-FCD58DF747A5Q52641738-907A2B85-FEBD-4A28-99F4-140EC29DBB98
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Selective neuronal vulnerability in Parkinson disease.
@en
Selective neuronal vulnerability in Parkinson disease.
@nl
type
label
Selective neuronal vulnerability in Parkinson disease.
@en
Selective neuronal vulnerability in Parkinson disease.
@nl
prefLabel
Selective neuronal vulnerability in Parkinson disease.
@en
Selective neuronal vulnerability in Parkinson disease.
@nl
P2860
P356
P1476
Selective neuronal vulnerability in Parkinson disease.
@en
P2093
D James Surmeier
José A Obeso
P2860
P2888
P304
P356
10.1038/NRN.2016.178
P407
P577
2017-01-01T00:00:00Z